Reports
Sale
Ophthalmic Disease Therapeutics Market Size, Trends, Report: By Diseases Type: Glaucoma, Dry Eye Diseases, Retinal Diseases, Allergy and Infections, Diabetic Retinopathy, Others; By Drug Class; By Route of Administration; By Dosages Form; By Distribution Channel; By End User; By Regional Analysis; Supplier Landscape; 2024-2032
Ophthalmic Disease Therapeutics Market Outlook
The ophthalmic disease therapeutics market size was valued at USD 35.75 billion in 2023, driven by the rising number of disorders associated with eyes across the globe. The market size is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to achieve a value of USD 62.48 billion by 2032.
Ophthalmic Diseases: Introduction
Diseases or disorders that infect or impact the eye health in humans are known as ophthalmic diseases. With ever-changing lifestyle changes it is very common to suffer from ophthalmic diseases in today’s time. These disorders may also be the result of some other diseases such as diabetes. The ophthalmic disorder that occurs in diabetic patients is known as diabetic retinopathy (DR).
Ophthalmic Disease Therapeutics Market Analysis
The continuous integration of advanced technologies to predict the treatment demand for ophthalmic diseases is among the major trends propelling the market growth. The rise in ophthalmic disorders or diseases in diabetic patients is also driving market growth. The market has also been witnessing continuous growth as research and development activities associated with the discovery of new drugs or treatments for ophthalmic diseases are on the rise. For example, the drug analysis of an experimental drug 32-134D at Wilmer Eye Institute, Johns Hopkins Medicine was proven to be effective in reducing HIF levels in diseased eyes. This drug analysis was proven effective against slow vision loss in diabetic patients. Eye conditions leading to vision loss are common complications of diabetes and about 8 million Americans are impacted by them. According to the National Institutes of Health, these numbers are expected to nearly double by 2040.
The ophthalmic disease therapeutics market growth is also influenced by the increasing number of clinical trials such as targeted retinal photocoagulation TRP has been proven effective against diabetic retinopathy (DR) and may become a substitute for Pan Retinal Photocoagulation (PRP) in the coming years. The combinational therapy produced out of TRP with intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) drugs can also be a potential new approach to expand the treatment regimen for the treatment of diabetic retinopathy. This combinational therapy has been effective on other retinal vascular diseases. The increasing awareness about combinational therapies among people and eye care professionals is also expected to drive market growth.
Ophthalmic Disease Therapeutics Market Segmentations
Market Breakup by Disease Type
- Glaucoma
- Dry Eye Diseases
- Retinal Diseases
- Allergy & infections
- Diabetic Retinopathy
- Others
Market Breakup by Drug Class
- Anti-inflammatory Drugs
- Anti-infective Drugs
- Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
- Anti-glaucoma Drugs
- Corticosteroids
- Others
Market Breakup by Route of Administration
- Topical
- Oral
- Intravenous
Market Breakup by Dosages Form
- Solid
- Liquid
- Semi- Solid
Market Breakup by Distribution Channel
- Hospitals Pharmacies
- Retail pharmacies
- Online Pharmacies
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Homecare Settings
- Others
Market Breakup by Region-7MM
- United States
- EU-4 and the United Kingdom
- Japan
Ophthalmic Disease Therapeutics Market Overview
The market has been witnessing significant growth due to the increasing geriatric population worldwide. This is due to the development of age-related macular degeneration (AMD) in which the macula is impacted causing central vision loss. The increasing demand for treatment of such eye disorders for the aged population is continuously driving the market growth. The increasing prevalence of chronic diseases such as diabetes is also driving the market growth as it can also cause diabetic retinopathy. The key players in the market are targeting more towards the development of new and improved treatments and drugs.
The increasing research and development activities to develop advanced drugs for the treatment of ophthalmic disorders that may cause total blindness, in the long run, are continuously driving the ophthalmic disease therapeutics market growth. The early diagnosis and timely management of eye conditions such as diabetic retinopathy have been proven effective however, a lack of awareness about the treatments and diagnostic measures for ophthalmic diseases is anticipated to restrict the market growth. According to WHO, refractive errors and cataracts are the leading cause of vision impairment and blindness.
Geographically, North America is leading the global market and is expected to lead throughout the forecast period. The presence of a geriatric population and diabetic patient pool is majorly contributing to the ophthalmic disease therapeutics market share. Eye diseases such as age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma are the leading causes of blindness and low vision in the United States. Diabetic retinopathy (DR) is a common complication of diabetes. It is the leading cause of blindness in American adults.
Ophthalmic Disease Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Alcon
- Novartis AG
- Bausch Health Companies Inc.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc
- Allergan
- Bayer AG
- Genentech, Inc.
- Nicox
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Dosages Form |
|
| Breakup by Distribution Channel |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Ophthalmic Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ophthalmic Disease Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2016-2031)
5.2 United States Ophthalmic Disease Epidemiology (2016-2031)
5.3 EU-4 and United Kingdom Ophthalmic Disease Epidemiology (2016-2031)
5.4 Japan Ophthalmic Disease Epidemiology (2016-2031)
6 Ophthalmic Disease Therapeutics Market Overview
6.1 Ophthalmic Disease Therapeutics Market Historical Value (2017-2023)
6.2 Ophthalmic Disease Therapeutics Market Forecast Value (2024-2032)
7 Ophthalmic Disease Therapeutics Market Landscape
7.1 Ophthalmic Disease Therapeutics Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Ophthalmic Disease Therapeutics Product Landscape
7.2.1 Analysis by Disease Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Ophthalmic Disease Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Ophthalmic Disease Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Ophthalmic Disease Therapeutics Market Segmentation
11.1 Ophthalmic Disease Therapeutics Market by Disease Type
11.1.1 Market Overview
11.1.2 Glaucoma
11.1.3 Dry Eye Disease
11.1.4 Retinal Disease
11.1.5 Allergy and Infections
11.1.6 Diabetic Retinopathy
11.1.7 Others
11.2 Ophthalmic Disease Therapeutics Market by Drug Class
11.2.1 Market Overview
11.2.2 Anti-inflammatory Drugs
11.2.3 Anti-infective Drugs
11.2.4 Anti-VEGF (Vascular Endothelial Growth Factor) Drugs
11.2.5 Anti-glaucoma Drugs
11.2.6 Corticosteroids
11.2.7 Others
11.3 Ophthalmic Disease Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Topical
11.3.3 Oral
11.3.4 Intravenous
11.4 Ophthalmic Disease Therapeutics Market by Dosages Form
11.4.1 Market Overview
11.4.2 Solid
11.4.3 Liquid
11.4.4 Semi- Solid
11.5 Ophthalmic Disease Therapeutics Market by Distribution Channel
11.5.1 Market Overview
11.5.2 Hospitals Pharmacies
11.5.3 Retail pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Ophthalmic Disease Therapeutics Market by End User
11.6.1 Market Overview
11.6.2 Hospitals
11.6.3 Clinics
11.6.4 Ambulatory Surgical Centers
11.6.5 Homecare Settings
11.6.6 Others
11.7 Ophthalmic Disease Therapeutics Market by Region-7MM
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan
12 United States Ophthalmic Disease Therapeutics Market
12.1 U.S. Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
12.2 U.S. Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Drug Class
13 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market
13.1 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Drug Class
14 Japan Ophthalmic Disease Therapeutics Market
14.1 Japan Ophthalmic Disease Therapeutics Market Historical Size (2017-2023)
14.2 Japan Ophthalmic Disease Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Drug Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Pfizer Inc.
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisition
21.1.5 Certifications
21.2 Alcon
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisition
21.2.5 Certifications
21.3 Novartis AG
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisition
21.3.5 Certifications
21.4 Bausch Health Companies Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisition
21.4.5 Certifications
21.5 Merck & Co., Inc.
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisition
21.5.5 Certifications
21.6 Regeneron Pharmaceuticals Inc
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisition
21.6.5 Certifications
21.7 Allergan
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisition
21.7.5 Certifications
21.8 Bayer AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisition
21.8.5 Certifications
21.9 Genentech, Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisition
21.9.5 Certifications
21.10 Nicox
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisition
21.10.5 Certifications
22 Ophthalmic Disease Therapeutics Market - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 35.75 billion in 2023, driven by the increasing geriatric patient pool.
The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032, likely to reach a market value of USD 62.48 billion by 2032.
The increasing research and development activities to develop advanced drugs to treat ophthalmic disorders is a major factor driving the demand for the market.
The increasing clinical trials and approvals for new innovative drugs is a major trend influencing the market growth.
The major regions of the market include United States, Japan, and EU-4 and the United Kingdom.
Different ophthalmic diseases include glaucoma, dry eye diseases, retinal diseases, allergies and infections, diabetic retinopathy, among others.
The different drug classes used in ophthalmic disease are anti-inflammatory drugs, anti-infective drugs, anti-VEGF (Vascular Endothelial Growth Factor) drugs, anti-glaucoma drugs, and corticosteroids, among others.
The routes of administration include topical, oral, and intravenous.
Different dosage forms include solid, liquid, and semi-solid.
They find wide applications in dental caries prevention, dental erosion prevention, and dentin hypersensitivity treatment, among others.
The end users in the market include hospitals, clinics, ambulatory surgical centers, and homecare settings, among others.
Distribution channels include hospitals pharmacies, retail pharmacies, online pharmacies, and others.
Key players involved in the market are Pfizer Inc., Alcon, Novartis AG, Bausch Health Companies Inc., Merck & Co., Inc., Regeneron Pharmaceuticals Inc., Allergan, Bayer AG, Genentech, Inc., and Nicox.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER